Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 44. More products

LACOSAMIDE

All strengths: Limited Use — Reason for Use code 430 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 430 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Topiramate (Topamax Sprinkle): general benefit, Limited Use 321, Not a benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Ach-Lacosamide · DIN 02489287 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Lacosamide · DIN 02489287 Manufacturer: Accord Healthcare Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-04-27 · brand ACH-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97936 · Verify on the e-Formulary ↗ (DIN 02489287)

Source record
DIN 02489287: Ach-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id ACH Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489287 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97936
Interchangeable products
Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: active shortage (reported 2022-09-22, last updated 2022-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489287
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lacosamide · DIN 02475332 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lacosamide · DIN 02475332 Manufacturer: Auro Pharma Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand AURO-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96571 · Verify on the e-Formulary ↗ (DIN 02475332)

Source record
DIN 02475332: Auro-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id AUR Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475332 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96571
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475332
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Lacosamide · DIN 02488388 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Lacosamide · DIN 02488388 Manufacturer: Jamp Pharma Corporation; listing date 2020-05-29 Health Canada: Marketed since 2020-03-06 · brand JAMP-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97848 · Verify on the e-Formulary ↗ (DIN 02488388)

Source record
DIN 02488388: Jamp-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id JPC Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02488388 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97848
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2022-07-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02488388
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lacosamide · DIN 02512874 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lacosamide · DIN 02512874 Manufacturer: Sanis Health Inc.; listing date 2021-11-30 Health Canada: Marketed since 2024-11-26 · brand LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100212 · Verify on the e-Formulary ↗ (DIN 02512874)

Source record
DIN 02512874: Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id SAI Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512874 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100212
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2025-01-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512874
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Lacosamide · DIN 02490544 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Lacosamide · DIN 02490544 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-01-31 Health Canada: Marketed since 2019-11-25 · brand MINT-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98058 · Verify on the e-Formulary ↗ (DIN 02490544)

Source record
DIN 02490544: Mint-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id MIN Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490544 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98058
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2021-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02490544
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pharma-Lacosamide · DIN 02478196 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pharma-Lacosamide · DIN 02478196 Manufacturer: Pharmascience Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand PHARMA-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Pharma-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96892 · Verify on the e-Formulary ↗ (DIN 02478196)

Source record
DIN 02478196: Pharma-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id PMS Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478196 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96892
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2025-01-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478196
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Lacosamide · DIN 02474670 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Lacosamide · DIN 02474670 Manufacturer: Sandoz Canada Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand SANDOZ LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96485 · Verify on the e-Formulary ↗ (DIN 02474670)

Source record
DIN 02474670: Sandoz Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id SDZ Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474670 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96485
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2024-09-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474670
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lacosamide · DIN 02472902 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Lacosamide · DIN 02472902 Manufacturer: Teva Canada Limited; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand TEVA-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96224 · Verify on the e-Formulary ↗ (DIN 02472902)

Source record
DIN 02472902: Teva-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id TEV Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472902 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96224
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Vimpat · DIN 02357615 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: resolved shortage (ended 2026-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02472902
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Vimpat · DIN 02357615 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Vimpat · DIN 02357615 Manufacturer: UCB Canada Inc.; listing date 2012-04-24 Health Canada: Marketed since 2010-10-21 · brand VIMPAT · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84272 · Verify on the e-Formulary ↗ (DIN 02357615)

Source record
DIN 02357615: Vimpat Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id UCB Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.5250; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357615 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84272
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 ZDS-Lacosamide · DIN 02487802 · $0.6313
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357615
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ZDS-Lacosamide · DIN 02487802 · 50mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
ZDS-Lacosamide · DIN 02487802 Manufacturer: Zydus; listing date 2019-12-20 Health Canada: Marketed since 2025-11-17 · brand ZDS-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 50 MG · company Zydus pharmaceuticals (canada) inc · schedule Prescription
Check this DIN again · Health Canada product record

ZDS-Lacosamide: Formulary list price $0.6313/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6313 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97796 · Verify on the e-Formulary ↗ (DIN 02487802)

Source record
DIN 02487802: ZDS-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200148; group id 431; item number 1075; lccId 00221; manufacturer id ZDS Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6313; ministry $0.6313 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487802 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97796
Interchangeable products
Ach-Lacosamide · DIN 02489287 · $0.6313 Auro-Lacosamide · DIN 02475332 · $0.6313 Jamp-Lacosamide · DIN 02488388 · $0.6313 Lacosamide · DIN 02512874 · $0.6313 Mint-Lacosamide · DIN 02490544 · $0.6313 NRA-Lacosamide · DIN 02499568 · $0.6313 Pharma-Lacosamide · DIN 02478196 · $0.6313 Sandoz Lacosamide · DIN 02474670 · $0.6313 Teva-Lacosamide · DIN 02472902 · $0.6313 Vimpat · DIN 02357615 · $0.6313
Shortage status: resolved shortage (ended 2022-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487802
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Lacosamide · DIN 02489295 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Lacosamide · DIN 02489295 Manufacturer: Accord Healthcare Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-04-27 · brand ACH-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97937 · Verify on the e-Formulary ↗ (DIN 02489295)

Source record
DIN 02489295: Ach-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id ACH Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489295 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97937
Interchangeable products
Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: active shortage (reported 2022-09-22, last updated 2022-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489295
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lacosamide · DIN 02475340 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lacosamide · DIN 02475340 Manufacturer: Auro Pharma Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand AURO-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96572 · Verify on the e-Formulary ↗ (DIN 02475340)

Source record
DIN 02475340: Auro-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475340 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96572
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: resolved shortage (ended 2024-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475340
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Lacosamide · DIN 02488396 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Lacosamide · DIN 02488396 Manufacturer: Jamp Pharma Corporation; listing date 2020-05-29 Health Canada: Marketed since 2020-03-06 · brand JAMP-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97849 · Verify on the e-Formulary ↗ (DIN 02488396)

Source record
DIN 02488396: Jamp-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02488396 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97849
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: resolved shortage (ended 2022-10-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02488396
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lacosamide · DIN 02512882 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lacosamide · DIN 02512882 Manufacturer: Sanis Health Inc.; listing date 2021-11-30 Health Canada: Marketed since 2024-11-26 · brand LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100213 · Verify on the e-Formulary ↗ (DIN 02512882)

Source record
DIN 02512882: Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512882 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100213
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: resolved shortage (ended 2025-01-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512882
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Lacosamide · DIN 02490552 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Lacosamide · DIN 02490552 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-01-31 Health Canada: Marketed since 2019-11-25 · brand MINT-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98059 · Verify on the e-Formulary ↗ (DIN 02490552)

Source record
DIN 02490552: Mint-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id MIN Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490552 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98059
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02490552
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pharma-Lacosamide · DIN 02478218 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pharma-Lacosamide · DIN 02478218 Manufacturer: Pharmascience Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand PHARMA-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Pharma-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96893 · Verify on the e-Formulary ↗ (DIN 02478218)

Source record
DIN 02478218: Pharma-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id PMS Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478218 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96893
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: resolved shortage (ended 2019-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478218
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Lacosamide · DIN 02474689 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Lacosamide · DIN 02474689 Manufacturer: Sandoz Canada Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand SANDOZ LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96486 · Verify on the e-Formulary ↗ (DIN 02474689)

Source record
DIN 02474689: Sandoz Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id SDZ Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474689 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96486
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: resolved shortage (ended 2025-04-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474689
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lacosamide · DIN 02472910 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Lacosamide · DIN 02472910 Manufacturer: Teva Canada Limited; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand TEVA-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96225 · Verify on the e-Formulary ↗ (DIN 02472910)

Source record
DIN 02472910: Teva-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id TEV Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472910 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96225
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Vimpat · DIN 02357623 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: active shortage (reported 2026-06-03, estimated to end 2026-08-10, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02472910
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Vimpat · DIN 02357623 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Vimpat · DIN 02357623 Manufacturer: UCB Canada Inc.; listing date 2012-04-24 Health Canada: Marketed since 2010-10-21 · brand VIMPAT · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84273 · Verify on the e-Formulary ↗ (DIN 02357623)

Source record
DIN 02357623: Vimpat Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id UCB Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.5000; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357623 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84273
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 ZDS-Lacosamide · DIN 02487810 · $0.8750
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357623
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ZDS-Lacosamide · DIN 02487810 · 100mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
ZDS-Lacosamide · DIN 02487810 Manufacturer: Zydus; listing date 2019-12-20 Health Canada: Marketed since 2025-11-17 · brand ZDS-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 100 MG · company Zydus pharmaceuticals (canada) inc · schedule Prescription
Check this DIN again · Health Canada product record

ZDS-Lacosamide: Formulary list price $0.8750/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8750 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97797 · Verify on the e-Formulary ↗ (DIN 02487810)

Source record
DIN 02487810: ZDS-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200149; group id 431; item number 1076; lccId 00221; manufacturer id ZDS Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8750; ministry $0.8750 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487810 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97797
Interchangeable products
Ach-Lacosamide · DIN 02489295 · $0.8750 Auro-Lacosamide · DIN 02475340 · $0.8750 Jamp-Lacosamide · DIN 02488396 · $0.8750 Lacosamide · DIN 02512882 · $0.8750 Mint-Lacosamide · DIN 02490552 · $0.8750 NRA-Lacosamide · DIN 02499576 · $0.8750 Pharma-Lacosamide · DIN 02478218 · $0.8750 Sandoz Lacosamide · DIN 02474689 · $0.8750 Teva-Lacosamide · DIN 02472910 · $0.8750 Vimpat · DIN 02357623 · $0.8750
Shortage status: resolved shortage (ended 2022-07-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487810
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Lacosamide · DIN 02489309 · 150mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Lacosamide · DIN 02489309 Manufacturer: Accord Healthcare Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-04-27 · brand ACH-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 150 MG · company Accord healthcare inc · schedule Prescription
Check this DIN again · Health Canada product record

Ach-Lacosamide: Formulary list price $1.1763/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1763 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97938 · Verify on the e-Formulary ↗ (DIN 02489309)

Source record
DIN 02489309: Ach-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200150; group id 431; item number 1077; lccId 00221; manufacturer id ACH Source form: Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1763; ministry $1.1763 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489309 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97938
Interchangeable products
Auro-Lacosamide · DIN 02475359 · $1.1763 Jamp-Lacosamide · DIN 02488418 · $1.1763 Lacosamide · DIN 02512890 · $1.1763 Mint-Lacosamide · DIN 02490560 · $1.1763 NRA-Lacosamide · DIN 02499584 · $1.1763 Pharma-Lacosamide · DIN 02478226 · $1.1763 Sandoz Lacosamide · DIN 02474697 · $1.1763 Teva-Lacosamide · DIN 02472929 · $1.1763 Vimpat · DIN 02357631 · $1.1763 ZDS-Lacosamide · DIN 02487829 · $1.1763
Shortage status: active shortage (reported 2022-09-22, last updated 2022-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489309
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lacosamide · DIN 02475359 · 150mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lacosamide · DIN 02475359 Manufacturer: Auro Pharma Inc.; listing date 2018-11-29 Health Canada: Marketed since 2018-10-01 · brand AURO-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 150 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lacosamide: Formulary list price $1.1763/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1763 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96573 · Verify on the e-Formulary ↗ (DIN 02475359)

Source record
DIN 02475359: Auro-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200150; group id 431; item number 1077; lccId 00221; manufacturer id AUR Source form: Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1763; ministry $1.1763 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02475359 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96573
Interchangeable products
Ach-Lacosamide · DIN 02489309 · $1.1763 Jamp-Lacosamide · DIN 02488418 · $1.1763 Lacosamide · DIN 02512890 · $1.1763 Mint-Lacosamide · DIN 02490560 · $1.1763 NRA-Lacosamide · DIN 02499584 · $1.1763 Pharma-Lacosamide · DIN 02478226 · $1.1763 Sandoz Lacosamide · DIN 02474697 · $1.1763 Teva-Lacosamide · DIN 02472929 · $1.1763 Vimpat · DIN 02357631 · $1.1763 ZDS-Lacosamide · DIN 02487829 · $1.1763
Shortage status: resolved shortage (ended 2024-12-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475359
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Lacosamide · DIN 02488418 · 150mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Lacosamide · DIN 02488418 Manufacturer: Jamp Pharma Corporation; listing date 2020-05-29 Health Canada: Marketed since 2020-03-06 · brand JAMP-LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 150 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Lacosamide: Formulary list price $1.1763/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1763 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97850 · Verify on the e-Formulary ↗ (DIN 02488418)

Source record
DIN 02488418: Jamp-Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200150; group id 431; item number 1077; lccId 00221; manufacturer id JPC Source form: Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1763; ministry $1.1763 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02488418 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97850
Interchangeable products
Ach-Lacosamide · DIN 02489309 · $1.1763 Auro-Lacosamide · DIN 02475359 · $1.1763 Lacosamide · DIN 02512890 · $1.1763 Mint-Lacosamide · DIN 02490560 · $1.1763 NRA-Lacosamide · DIN 02499584 · $1.1763 Pharma-Lacosamide · DIN 02478226 · $1.1763 Sandoz Lacosamide · DIN 02474697 · $1.1763 Teva-Lacosamide · DIN 02472929 · $1.1763 Vimpat · DIN 02357631 · $1.1763 ZDS-Lacosamide · DIN 02487829 · $1.1763
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02488418
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lacosamide · DIN 02512890 · 150mg · tablet

Limited Use — Reason for Use code 430 requiredMarketed · checked 2026-09-02
Write on scriptLU code 430 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 430
Reason for Use code 430 As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lacosamide · DIN 02512890 Manufacturer: Sanis Health Inc.; listing date 2021-11-30 Health Canada: Marketed since 2024-11-26 · brand LACOSAMIDE · ATC N03AX18 LACOSAMIDE · form Tablet · route Oral · ingredients LACOSAMIDE 150 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lacosamide: Formulary list price $1.1763/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1763 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100214 · Verify on the e-Formulary ↗ (DIN 02512890)

Source record
DIN 02512890: Lacosamide Raw flags: sec12=Y, sec3=Y Item: 281200150; group id 431; item number 1077; lccId 00221; manufacturer id SAI Source form: Tab; strength: 150mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1763; ministry $1.1763 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02512890 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100214
Interchangeable products
Ach-Lacosamide · DIN 02489309 · $1.1763 Auro-Lacosamide · DIN 02475359 · $1.1763 Jamp-Lacosamide · DIN 02488418 · $1.1763 Mint-Lacosamide · DIN 02490560 · $1.1763 NRA-Lacosamide · DIN 02499584 · $1.1763 Pharma-Lacosamide · DIN 02478226 · $1.1763 Sandoz Lacosamide · DIN 02474697 · $1.1763 Teva-Lacosamide · DIN 02472929 · $1.1763 Vimpat · DIN 02357631 · $1.1763 ZDS-Lacosamide · DIN 02487829 · $1.1763
Shortage status: resolved shortage (ended 2025-01-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512890
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS VIMPAT (lacosamide) is indicated as:  Monotherapy in the management of partial-onset seizures in adult (>18 years of age) patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy (see 14 CLINICAL TRIALS).  Adjunctive therapy in the management of partial-onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of VIMPAT in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (>65 years of age): The clinical experience with VIMPAT in elderly patients with epilepsy is limited. Caution should be exercised during dose titration and age -associated decreased renal clearance should be considered in elderly patients (see 7.1.4 Geriatrics, 4.2 Recommended Dose and Dosage Adjustment, Geriatrics and 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). … https://pdf.hres.ca/dpd_pm/00068756.PDF PM date: September 22, 2010 Source product: VIMPAT; DIN 02357615; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ach-Lacosamide · DIN 02489287 Shortage status: active shortage (reported 2022-09-22, last updated 2022-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489287

Check this DIN again

Ach-Lacosamide · DIN 02489295 Shortage status: active shortage (reported 2022-09-22, last updated 2022-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489295

Check this DIN again

Teva-Lacosamide · DIN 02472910 Shortage status: active shortage (reported 2026-06-03, estimated to end 2026-08-10, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02472910

Check this DIN again

Ach-Lacosamide · DIN 02489309 Shortage status: active shortage (reported 2022-09-22, last updated 2022-10-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489309

Check this DIN again